查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1616824

按产品、技术、适应症、应用、地区、范围和预测划分的全球免疫肿瘤检测市场规模

Global Immuno Oncology Assays Market Size By Product, By Technology (Polymerase Chain Reaction, Flow Cytometry), By Indication, By Application, By Geographic Scope and Forecast, By Geographic Scope and Forecast
出版日期: | 出版商: Verified Market Research | 英文 202 Pages | 商品交期: 2-3个工作天内

价格
简介目录

免疫肿瘤学检测市场规模及预测

2024 年免疫肿瘤检测市场规模为 38.7 亿美元，预计到 2031 年将达到 57.8 亿美元，2024 年至 2031 年复合年增长率为 5.70%。全球免疫肿瘤学测试是指一系列旨在评估对癌症的免疫反应并评估免疫疗法治疗效果的诊断测试。这些测试对于识别免疫检查点抑制剂和肿瘤浸润淋巴细胞等特定生物标记至关重要，这有助于为癌症患者制定个人化治疗计划。免疫肿瘤学检测的应用涵盖多种癌症类型，有助于指导临床决策、监测治疗反应和预测患者结果。

随着生物标记发现、新一代定序技术的进步以及免疫治疗研究投资的增加，该领域的未来充满希望。随着个人化癌症治疗需求的增加，提高癌症治疗的精确度并提高患者存活率，全球免疫肿瘤检测市场预计将显着扩大。

免疫肿瘤学检测的全球市场动态

塑造全球免疫肿瘤检测市场的关键市场动态

主要市场驱动因子

癌症发生率增加：

全球癌症发生率的增加是免疫肿瘤检测市场的关键推动因素。据世界卫生组织 (WHO) 称，受癌症影响的人数预计将从 2020 年的 1930 万人增加到 2040 年的 2950 万人。癌症发生率的快速增加推动了对有效诊断工具的需求，包括免疫肿瘤学检测。

免疫疗法的流行使用：

免疫疗法在癌症治疗中的普及和成功正在推动市场发展。美国癌症协会报告称，近年来批准的新癌症治疗方法中约有 50% 是免疫疗法，这凸显了需要能够识别这些治疗方法的合适候选药物的检测方法。

生物标记发现的进展：

生物标记研究和技术的创新正在推动免疫肿瘤学检测的发展。美国国立卫生研究院 (NIH) 报告称，从 2021 年到 2022 年，癌症生物标记的研究经费将增加 17%，旨在提高检测准确性并提高其预测治疗效果的有效性的研究正在推进。

增加政府资助和支持：

各国政府正在增加对癌症研究和免疫疗法开发的投资，加强免疫肿瘤学检测市场。例如，美国国家癌症研究所（NCI）已在2023年拨款约60亿美元用于癌症研究，其中大部分用于免疫疗法和相关诊断技术的开发。

主要挑战

检测成本高：

先进的免疫肿瘤学检测的开发和实施成本高昂，某些医疗机构和患者的使用可能受到限制。高成本也可能阻碍广泛采用，特别是在预算限制令人担忧的发展中地区。

监理障碍：

瞭解免疫肿瘤学检测的监管环境既复杂又耗时。临床验证和批准的严格监管要求可能会延迟新检测方法的市场推出，并影响患者及时获得创新诊断。

资料解释的复杂性：

由于免疫反应和肿瘤生物学的复杂性，解释免疫肿瘤学检测的结果可能很困难。临床医生可能需要专门的培训才能准确解释结果，这使得将这些测试融入日常临床实践变得复杂。

标准化有限：

不同免疫肿瘤学检测之间缺乏标准化可能会导致结果和结局的差异。这种差异使临床医生很难比较结果，并使监管审批过程更加复杂。

主要趋势：

人工智慧 (AI) 与机器学习的整合：

人工智慧和机器学习在免疫肿瘤学检测数据分析的应用正在迅速普及。这些技术可以增强数据解释、识别模式并提高治疗效果预测的准确性，最终改善患者的治疗结果。

个人化医疗重点：

随着对个人化医疗的日益重视，免疫肿瘤学检测在根据肿瘤特征和免疫特征为个别患者定制治疗方面发挥着重要作用。预计这一趋势将推动对更复杂和更精确检测的需求。

伙伴关係与联合研究：

生技公司、研究机构和医疗保健提供者之间的合作伙伴关係正在不断加强，以促进免疫肿瘤学检测的创新。这些合作伙伴关係旨在彙集专业知识和资源，以有效开发新的诊断工具并将其商业化。

进入新兴市场：

随着医疗保健基础设施的改善和癌症治疗意识的提高，免疫肿瘤学测试市场正在扩展到新兴市场。对于希望向传统服务欠缺地区扩张的公司来说，这一趋势代表着一个重大的成长机会。

目录

第一章全球免疫肿瘤检测市场：简介

  • 市场概览
  • 调查范围
  • 先决条件

第 2 章执行摘要

第三章验证市场情报研究方法

  • 资料探勘
  • 验证
  • 主要来源
  • 资料来源列表

第 4 章免疫肿瘤检测的全球市场前景

  • 摘要
  • 市场动态
    • 促进因素
    • 抑制因素
    • 机会
  • 波特的五力模型
  • 价值链分析

第 5 章免疫肿瘤学检测的全球市场（副产品）

  • 摘要
  • 消耗品
  • 软体与服务
  • 设备

第 6 章免疫肿瘤学检测的全球市场：按应用划分

  • 摘要
  • 调查申请
  • 临床诊断

第 7 章免疫肿瘤学检测的全球市场：依适应症划分

  • 摘要
  • 肺癌
  • 乳癌
  • 大肠癌
  • 膀胱癌
  • 黑色素瘤
  • 其他癌症

第 8 章按技术划分的免疫肿瘤学检测的全球市场

  • 摘要
  • 聚合□炼式反应 (PCR)
  • 流式细胞仪
  • 免疫分析
  • 次世代定序 (NGS)
  • 原位杂交 (ISH)

第 9 章全球免疫肿瘤检测市场：按地区

  • 摘要
  • 北美
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 德国
    • 英国
    • 法国
    • 欧洲其他地区
  • 亚太地区
    • 中国
    • 日本
    • 印度
    • 其他亚太地区
  • 世界其他地区
    • 拉丁美洲
    • 中东/非洲

第 10 章全球免疫肿瘤检测市场：竞争格局

  • 摘要
  • 公司市场排名
  • 主要发展策略

第十一章公司简介

  • Agilent Technologies, Inc.
  • Thermo Fisher Scientific, Inc.
  • PerkinElmer, Inc.
  • Illumina, Inc.
  • PerkinElmer, Inc.
  • Crown Bioscience Inc.
  • InSphero, Inc.
  • Merck & Company, Inc.
  • F.Hoffmann-La Roche Ltd.
  • HTG Molecular Diagnostics, Inc.

第12章主要进展

  • 产品发布/开发
  • 併购
  • 业务扩展
  • 合作伙伴与联盟

第13章附录

  • 相关研究
简介目录
Product Code: 7664

Immuno Oncology Assays Market Size And Forecast

Immuno Oncology Assays Market size was valued at USD 3.87 Billion in 2024 and is projected to reach USD 5.78 Billion by 2031 , growing at a CAGR of 5.70% from 2024 to 2031. Global immuno-oncology assays refer to a range of diagnostic tests designed to evaluate the immune response to cancer and assess the effectiveness of immunotherapy treatments. These assays are crucial for identifying specific biomarkers, such as immune checkpoint inhibitors and tumor-infiltrating lymphocytes, which help tailor personalized treatment plans for cancer patients. The applications of immuno-oncology assays extend across various cancer types, guiding clinical decision-making, monitoring treatment responses, and predicting patient outcomes.

The future of this field looks promising, driven by advancements in biomarker discovery, next-generation sequencing technologies, and increasing investments in immunotherapy research. As the demand for personalized cancer treatment grows, the global immuno-oncology assays market is expected to expand significantly, enhancing the precision of cancer therapies and improving patient survival rates.

Global Immuno Oncology Assays Market Dynamics

The key market dynamics that are shaping the global immuno-oncology assays market include:

Key Market Drivers:

Rising Incidence of Cancer:

The increasing prevalence of cancer worldwide is a significant driver for the immuno-oncology assays market. According to the World Health Organization (WHO), cancer cases are expected to rise to 29.5 million globally by 2040, up from 19.3 million in 2020. This surge in cancer incidence is driving the demand for effective diagnostic tools, including immuno-oncology assays.

Growing Adoption of Immunotherapy:

The rising acceptance and success of immunotherapy in cancer treatment are propelling the market. A report by the American Cancer Society states that approximately 50% of new cancer drugs approved in recent years are immunotherapies, highlighting the need for assays that can identify suitable candidates for these treatments.

Advancements in Biomarker Discovery:

Innovations in biomarker research and technology are enhancing the development of immuno-oncology assays. The National Institutes of Health (NIH) reported a 17% increase in research funding for cancer biomarkers between 2021 and 2022, driving advancements that improve assay accuracy and effectiveness in predicting treatment responses.

Increased Government Funding and Support:

Governments are increasingly investing in cancer research and immunotherapy development, which bolsters the immuno-oncology assays market. For instance, the National Cancer Institute (NCI) in the U.S. allocated approximately $6 billion for cancer research in 2023, with a significant portion dedicated to advancing immunotherapy and related diagnostic technologies.

Key Challenges:

High Cost of Assays:

The development and implementation of advanced immuno-oncology assays can be expensive, which may limit access for some healthcare facilities and patients. High costs can also hinder widespread adoption, especially in developing regions where budget constraints are a concern.

Regulatory Hurdles:

Navigating the regulatory landscape for immuno-oncology assays can be complex and time-consuming. Stringent regulatory requirements for clinical validation and approval may delay the introduction of new assays into the market, impacting timely patient access to innovative diagnostics.

Data Interpretation Complexity:

The interpretation of results from immuno-oncology assays can be challenging due to the complexity of immune responses and tumor biology. Clinicians may require specialized training to accurately interpret the results, which can complicate the integration of these assays into routine clinical practice.

Limited Standardization:

There is a lack of standardization across different immuno-oncology assays, which can lead to variability in results and outcomes. This inconsistency makes it difficult for clinicians to compare results and makes regulatory approval processes more complicated.

Key Trends:

Integration of Artificial Intelligence (AI) and Machine Learning:

The use of AI and machine learning in the analysis of immuno-oncology assay data is gaining traction. These technologies can enhance data interpretation, identify patterns, and improve the accuracy of predictions related to treatment responses, ultimately leading to better patient outcomes.

Personalized Medicine Focus:

There is a growing emphasis on personalized medicine, with immuno-oncology assays playing a crucial role in tailoring treatments to individual patients based on their specific tumor characteristics and immune profiles. This trend is expected to drive the demand for more sophisticated and precise assays.

Partnerships and Collaborations:

Increasing collaborations between biotechnology companies, research institutions, and healthcare providers are emerging to foster innovation in immuno-oncology assays. These partnerships aim to combine expertise and resources to develop and commercialize new diagnostic tools effectively.

Expansion into Emerging Markets:

The immuno-oncology assays market is witnessing expansion into emerging markets as healthcare infrastructure improves and awareness of cancer treatments increases. This trend presents significant growth opportunities for companies looking to tap into previously underserved regions.

What's inside a VMR industry report?

Our reports include actionable data and forward-looking analysis that help you craft pitches, create business plans, build presentations and write proposals.

Global Immuno Oncology Assays Market Regional Analysis

Here is a more detailed regional analysis of the global immuno oncology assays market:

North America:

North America holds a dominant position in the Immuno-Oncology Assays market, primarily driven by the advanced healthcare infrastructure, significant investments in cancer research, and a high prevalence of cancer cases. The region is home to leading pharmaceutical and biotechnology companies that are actively engaged in the development of innovative immuno-oncology therapies. According to the National Cancer Institute (NCI), an estimated 1.9 million new cancer cases will be diagnosed in the U.S. in 2024, which underscores the urgent need for effective diagnostic and treatment options.

Additionally, the regulatory environment in North America, particularly in the United States, is supportive of rapid innovations in cancer diagnostics and therapeutics. The U.S. Food and Drug Administration (FDA) has expedited the approval process for immuno-oncology assays, facilitating quicker access to market. This regulatory advantage, combined with high healthcare spending per capita, enhances the region's leadership in the immuno-oncology assays market.

Asia Pacific:

The Asia Pacific region is the fastest-growing market for Immuno-Oncology Assays, fueled by a rising incidence of cancer and increasing healthcare expenditure. The region is witnessing a surge in cancer cases due to factors such as an aging population and lifestyle changes, making the development and implementation of immuno-oncology therapies critical. According to the World Health Organization (WHO), cancer cases in Asia are projected to reach over 7.1 million by 2030, highlighting a significant demand for advanced diagnostic tools and treatments.

Governments in countries like China, Japan, and India are investing heavily in cancer research and healthcare infrastructure to combat the rising cancer burden. For instance, the Chinese government allocated approximately $2.5 billion for cancer research in its latest five-year plan, which aims to improve cancer detection and treatment. This commitment is expected to accelerate the adoption of immuno-oncology assays in the region.

Global Immuno Oncology Assays Market: Segmentation Analysis

The Global Immuno Oncology Assays Market is segmented on the basis of Product, Application, Indication, Technology, and Geography.

Immuno Oncology Assays Market, By Product

  • Consumables
  • Software and Services
  • Instruments

Based on Product, the Global Immuno Oncology Assays Market is segmented into Consumables, Software and Services, and Instruments. The Consumables segment is currently dominating due to the recurring need for reagents, kits, and other consumables required for conducting assays. Conversely, the Software and Services segment is the fastest-growing, driven by the increasing demand for advanced data analysis and interpretation tools, as well as the rising adoption of integrated solutions that enhance laboratory efficiency.

Immuno Oncology Assays Market, By Application

  • Research Applications
  • Clinical Diagnostics

Based on Application, the Global Immuno Oncology Assays Market is segmented into Research Applications and Clinical Diagnostics. The Research Applications segment is currently dominating, driven by significant investments in cancer research and development initiatives aimed at discovering new biomarkers and therapies. However, the Clinical Diagnostics segment is the fastest-growing, fueled by the increasing adoption of immunotherapy in clinical settings and the demand for personalized treatment strategies.

Immuno Oncology Assays Market, By Indication

  • Lung Cancer
  • Breast Cancer
  • Colorectal Cancer
  • Bladder Cancer
  • Melanoma

Based on Indication, the Global Immuno Oncology Assays Market is segmented into Lung Cancer, Breast Cancer, Colorectal Cancer, Bladder Cancer and Melanoma. The Lung Cancer segment currently dominates due to the high prevalence of the disease and the significant advancements in immunotherapy options for lung cancer patients. Conversely, the Melanoma segment is the fastest-growing, fueled by the increasing incidence of melanoma and the rapid development of innovative immunotherapies, such as immune checkpoint inhibitors, which have shown promising results in clinical trials.

Immuno Oncology Assays Market, By Technology

  • Polymerase Chain Reaction (PCR)
  • Flow Cytometry
  • Immunoassay
  • Next-Generation Sequencing (NGS)
  • In Situ Hybridization (ISH)

Based on Application, the Global Immuno Oncology Assays Market is segmented into Polymerase Chain Reaction (PCR), Flow Cytometry, Immunoassay, Next-Generation Sequencing (NGS), and In Situ Hybridization (ISH). The Polymerase Chain Reaction (PCR) segment currently dominates due to its widespread use in detecting and amplifying specific DNA sequences, making it essential for various diagnostic applications in oncology. Conversely, the Next-Generation Sequencing (NGS) segment is the fastest-growing, driven by advancements in sequencing technologies and their capacity to analyze multiple genes simultaneously.

Immuno Oncology Assays Market, By Geography

  • North America
  • Europe
  • Asia Pacific
  • Rest of the World

Based on the Geography, the Global Immuno Oncology Assays Market are classified into North America, Europe, Asia Pacific, and Rest of World. North America holds a dominant position in the Immuno-Oncology Assays market, primarily driven by the advanced healthcare infrastructure, significant investments in cancer research, and a high prevalence of cancer cases. The Asia Pacific region is the fastest-growing market for Immuno-Oncology Assays, fueled by a rising incidence of cancer and increasing healthcare expenditure.

Key Players

  • The "Global Immuno Oncology Assays Market" study report will provide valuable insight with an emphasis on the global market. The major players in the market are
  • Agilent Technologies, Inc., PerkinElmer, Inc., Illumina, Inc., Thermo Fisher Scientific, Inc., Crown Bioscience Inc., Merck & Company, Inc., InSphero Inc., F. Hoffmann-La Roche Ltd., HTG Molecular Diagnostics, Inc.
  • Our
  • market analysis also entails a section solely dedicated to such major players wherein our analysts provide an insight into the financial statements of all the major players, along with its product benchmarking and SWOT analysis. The competitive landscape section also includes key development strategies, market share, and market ranking analysis of the above-mentioned players globally.
  • Global Immuno Oncology Assays Market: Recent Developments
  • In August 2024 Roche received U.S. Food and Drug Administration (FDA) approval for its new companion diagnostic assay that supports the use of a targeted therapy for breast cancer patients. This assay is designed to identify patients who are most likely to benefit from specific immuno-oncology treatments, thereby streamlining the patient selection process and improving treatment efficacy.
  • In July 2024 Thermo Fisher Scientific announced an expansion of its immuno-oncology portfolio with the introduction of new assays for tumor microenvironment analysis. These assays are designed to provide comprehensive insights into tumor behavior and immune response, supporting researchers in their quest to develop more effective immunotherapies. The company aims to enhance its leadership in precision medicine with these innovative solutions.
  • In June 2024 Agilent Technologies announced a partnership with leading academic institutions to develop novel immuno-oncology assays. This collaboration aims to accelerate research in tumor immunology and biomarker discovery, fostering innovation in the field. Agilent's CEO highlighted the importance of collaborative efforts in advancing immuno-oncology research and improving patient care through novel diagnostic solutions.

TABLE OF CONTENTS

1 INTRODUCTION OF GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET

  • 1.1 Overview of the Market
  • 1.2 Scope of Report
  • 1.3 Assumptions

2 EXECUTIVE SUMMARY

3 RESEARCH METHODOLOGY OF VERIFIED MARKET RESEARCH

  • 3.1 Data Mining
  • 3.2 Validation
  • 3.3 Primary Interviews
  • 3.4 List of Data Sources

4 GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET OUTLOOK

  • 4.1 Overview
  • 4.2 Market Dynamics
    • 4.2.1 Drivers
    • 4.2.2 Restraints
    • 4.2.3 Opportunities
  • 4.3 Porters Five Force Model
  • 4.4 Value Chain Analysis

5 GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET, BY PRODUCT

  • 5.1 Overview
  • 5.2 Consumables
  • 5.3 Software and Services
  • 5.4 Instruments

6 GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET, BY APPLICATION

  • 6.1 Overview
  • 6.2 Research Applications
  • 6.3 Clinical Diagnostics

7 GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET, BY INDICATION

  • 7.1 Overview
  • 7.2 Lung Cancer
  • 7.3 Breast Cancer
  • 7.4 Colorectal Cancer
  • 7.5 Bladder Cancer
  • 7.6 Melanoma
  • 7.7 Other Cancers

8 GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET, BY TECHNOLOGY

  • 8.1 Overview
  • 8.2 Polymerase Chain Reaction (PCR)
  • 8.3 Flow Cytometry
  • 8.4 Immunoassay
  • 8.5 Next-Generation Sequencing (NGS)
  • 8.6 In Situ Hybridization (ISH)

9 GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET, BY GEOGRAPHY

  • 9.1 Overview
  • 9.2 North America
    • 9.2.1 U.S.
    • 9.2.2 Canada
    • 9.2.3 Mexico
  • 9.3 Europe
    • 9.3.1 Germany
    • 9.3.2 U.K.
    • 9.3.3 France
    • 9.3.4 Rest of Europe
  • 9.4 Asia Pacific
    • 9.4.1 China
    • 9.4.2 Japan
    • 9.4.3 India
    • 9.4.4 Rest of Asia Pacific
  • 9.5 Rest of the World
    • 9.5.1 Latin America
    • 9.5.2 Middle East and Africa

10 GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET COMPETITIVE LANDSCAPE

  • 10.1 Overview
  • 10.2 Company Market Ranking
  • 10.3 Key Development Strategies

11 COMPANY PROFILES

  • 11.1 Agilent Technologies, Inc.
    • 11.1.1 Overview
    • 11.1.2 Financial Performance
    • 11.1.3 Product Outlook
    • 11.1.4 Key Developments
  • 11.2 Thermo Fisher Scientific, Inc.
    • 11.2.1 Overview
    • 11.2.2 Financial Performance
    • 11.2.3 Product Outlook
    • 11.2.4 Key Developments
  • 11.3 PerkinElmer, Inc.
    • 11.3.1 Overview
    • 11.3.2 Financial Performance
    • 11.3.3 Product Outlook
    • 11.3.4 Key Developments
  • 11.4 Illumina, Inc.
    • 11.4.1 Overview
    • 11.4.2 Financial Performance
    • 11.4.3 Product Outlook
    • 11.4.4 Key Developments
  • 11.5 PerkinElmer, Inc.
    • 11.5.1 Overview
    • 11.5.2 Financial Performance
    • 11.5.3 Product Outlook
    • 11.5.4 Key Developments
  • 11.6 Crown Bioscience Inc.
    • 11.6.1 Overview
    • 11.6.2 Financial Performance
    • 11.6.3 Product Outlook
    • 11.6.4 Key Development
  • 11.7 InSphero, Inc.
    • 11.7.1 Overview
    • 11.7.2 Financial Performance
    • 11.7.3 Product Outlook
    • 11.7.4 Key Developments
  • 11.8 Merck & Company, Inc.
    • 11.8.1 Overview
    • 11.8.2 Financial Performance
    • 11.8.3 Product Outlook
    • 11.8.4 Key Developments
  • 11.9 F.Hoffmann-La Roche Ltd.
    • 11.9.1 Overview
    • 11.9.2 Financial Performance
    • 11.9.3 Product Outlook
    • 11.9.4 Key Development
  • 11.10 HTG Molecular Diagnostics, Inc.
    • 11.10.1 Overview
    • 11.10.2 Financial Performance
    • 11.10.3 Product Outlook
    • 11.10.4 Key Development

12 KEY DEVELOPMENTS

  • 12.1 Product Launches/Developments
  • 12.2 Mergers and Acquisitions
  • 12.3 Business Expansions
  • 12.4 Partnerships and Collaborations

13 Appendix

  • 13.1 Related Research